Pfizer Inc (MIL:1PFE)
€ 24.625 -0.215 (-0.87%) Market Cap: 139.23 Bil Enterprise Value: 192.39 Bil PE Ratio: 35.39 PB Ratio: 1.61 GF Score: 64/100

Pfizer Inc at RBC Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 03:30PM GMT
Randall S. Stanicky
RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst

Great. Thanks, everybody, for joining us for our next virtual fireside chat here. We're kicking things off again with our next company. I'm Randall Stanicky, the pharmaceuticals analyst here at RBC Capital Markets.

And next up, we have Pfizer. The stock has proven resilient in the current pandemic. It's one of the names that we've been highlighting as defensive and wanting to own in this environment. And so with us to chat on the company, current dynamics and outlook here, Senior Vice President of Investor Relations, Chuck Triano.

And so Chuck, first, I just want to say thanks for joining us. It's great to have Pfizer at our conference. So thank you for that.

Questions & Answers

Randall S. Stanicky
RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst

And then to start off, let's jump into DMD and the market opportunity. This was something that you guys sounded pretty excited about on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot